Testa Analytical has released a differential refractometer that promises to significantly improve the accuracy of molecular weight determination in biopolymers and polymers. The instrument, designed specifically as an accessory for light scattering equipment, addresses one of the fundamental challenges in molecular characterisation: obtaining precise specific refractive index increment (dn/dc) values.
MIMETAS has introduced OrganoPlate UniFlow (UF), the first commercial platform offering unidirectional, gravity-driven pumpless flow systems for disease research. This innovation significantly advances tissue model development for pharmaceutical research by replicating physiological conditions without complex equipment.
CN Bio has launched an all-in-one drug-induced liver injury (DILI) testing kit that enables pharmaceutical researchers to conduct in-house hepatotoxicity screening using organ-on-chip technology. The system provides human-relevant data to support more informed candidate selection during preclinical development.
Cambridge scientists at EDX Medical Group have developed an innovative diagnostic test for prostate cancer that combines over 100 biomarkers with AI analysis, potentially transforming screening accuracy with sensitivity and specificity rates between 96-99%.
The Cambridge-based biotech company Shift Bioscience has announced the establishment of new facilities in Toronto, Canada, marking a strategic expansion of their AI capabilities in the development of virtual cell technology. The move follows their recent $16M seed funding round and positions the company to tap into North America’s rich pool of artificial intelligence talent.
Artificial Inc has successfully demonstrated the integration of NVIDIA’s BioNeMo generative AI platform with its laboratory orchestration system, showcasing capabilities for self-driving virtual screening in drug discovery applications. The proof-of-concept represents a significant technical advancement in applying AI technologies to pharmaceutical research workflows.
Sapio Sciences has announced significant leadership changes designed to strengthen its position in the AI-driven lab informatics sector. The Baltimore-based company, known for its “science-aware” platform, has appointed Mike Hampton as Chief Commercial Officer while simultaneously establishing a dedicated Scientific Office to enhance its research and development capabilities.
bioMérieux has announced the acquisition of SpinChip Diagnostics ASA, a privately held Norwegian company specialising in rapid immunoassay diagnostics. The €138 million deal will see bioMérieux acquire 100% ownership of the company, with a cash outlay of approximately €111 million, accounting for the 20% minority stake bioMérieux has held since March 2024.
Nuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.
Glox Therapeutics has announced strategic appointments to accelerate the development of its novel bacteriocin-based antibiotic platform, with Dr Michael Murray joining as Chair and Dr Nel Moore strengthening the Scientific Advisory Board. The Glasgow-based biotechnology company is pioneering a distinctive approach to combating antimicrobial resistance (AMR) through engineered protein bacteriocins that selectively target drug-resistant pathogens.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
